Naropin

Anesthesia procedures, Postoperative Pain, Labour + 1 more

Treatment

2 FDA approvals

20 Active Studies for Naropin

What is Naropin

Ropivacaine

The Generic name of this drug

Treatment Summary

Ropivacaine, sold under the brand name Naropin, is a local anaesthetic drug made up of two mirror-image molecules called enantiomers. Only one of the molecules, the ‘S’ enantiomer, is active and this is the form that is used in the drug. Ropivacaine is used to provide pain relief during medical procedures.

Naropin

is the brand name

image of different drug pills on a surface

Naropin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Naropin

Ropivacaine

1996

56

Approved as Treatment by the FDA

Ropivacaine, commonly known as Naropin, is approved by the FDA for 2 uses including Postoperative pain and Postoperative Pain .

Postoperative pain

Helps manage Postoperative pain

Postoperative Pain

Helps manage Postoperative pain

Effectiveness

How Naropin Affects Patients

Ropivacaine is a local anesthetic that does not have a different onset time, duration of action, or absorb into the bloodstream differently whether epinephrine is present or not.

How Naropin works in the body

Ropivacaine is a local anesthetic that works by blocking nerve signals. It does this by making it harder for the nerves to get excited and send messages, as well as by slowing down the speed at which those messages travel. It does this by blocking the sodium channel and keeping it from allowing the nerves to depolarize and send signals. How fast the anesthetic takes effect depends on the size, myelination, and speed of the nerves being blocked.

When to interrupt dosage

The recommended amount of Naropin is contingent upon the established condition, including Labour, Anesthesia procedures and Acute Pain. The dosage is subject to the mode of delivery (e.g. Epidural; Perineural or Solution - Epidural; Infiltration) featured in the table beneath.

Condition

Dosage

Administration

Labour

, 5.0 mg/mL, 10.0 mg/mL, 2.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 20.0 mg/mL, 4.0 mg/mL

, Parenteral, Injection, solution, Injection, solution - Parenteral, Injection, solution - Epidural; Infiltration; Perineural, Epidural, Epidural; Infiltration; Perineural, Epidural; Perineural, Injection, solution - Epidural, Injection, solution - Epidural; Perineural, Epidural; Infiltration, Injection, solution - Epidural; Infiltration, Liquid - Parenteral, Liquid, Solution - Epidural; Infiltration, Solution, Solution - Epidural, Infiltration, Injection - Epidural, Injection, Injection - Epidural; Infiltration; Perineural, Injection - Epidural; Perineural, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Kit, Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Injection - Epidural; Infiltration

Anesthesia procedures

, 5.0 mg/mL, 10.0 mg/mL, 2.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 20.0 mg/mL, 4.0 mg/mL

, Parenteral, Injection, solution, Injection, solution - Parenteral, Injection, solution - Epidural; Infiltration; Perineural, Epidural, Epidural; Infiltration; Perineural, Epidural; Perineural, Injection, solution - Epidural, Injection, solution - Epidural; Perineural, Epidural; Infiltration, Injection, solution - Epidural; Infiltration, Liquid - Parenteral, Liquid, Solution - Epidural; Infiltration, Solution, Solution - Epidural, Infiltration, Injection - Epidural, Injection, Injection - Epidural; Infiltration; Perineural, Injection - Epidural; Perineural, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Kit, Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Injection - Epidural; Infiltration

Acute Pain

, 5.0 mg/mL, 10.0 mg/mL, 2.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 20.0 mg/mL, 4.0 mg/mL

, Parenteral, Injection, solution, Injection, solution - Parenteral, Injection, solution - Epidural; Infiltration; Perineural, Epidural, Epidural; Infiltration; Perineural, Epidural; Perineural, Injection, solution - Epidural, Injection, solution - Epidural; Perineural, Epidural; Infiltration, Injection, solution - Epidural; Infiltration, Liquid - Parenteral, Liquid, Solution - Epidural; Infiltration, Solution, Solution - Epidural, Infiltration, Injection - Epidural, Injection, Injection - Epidural; Infiltration; Perineural, Injection - Epidural; Perineural, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Kit, Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Injection - Epidural; Infiltration

Postoperative Pain

, 5.0 mg/mL, 10.0 mg/mL, 2.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 20.0 mg/mL, 4.0 mg/mL

, Parenteral, Injection, solution, Injection, solution - Parenteral, Injection, solution - Epidural; Infiltration; Perineural, Epidural, Epidural; Infiltration; Perineural, Epidural; Perineural, Injection, solution - Epidural, Injection, solution - Epidural; Perineural, Epidural; Infiltration, Injection, solution - Epidural; Infiltration, Liquid - Parenteral, Liquid, Solution - Epidural; Infiltration, Solution, Solution - Epidural, Infiltration, Injection - Epidural, Injection, Injection - Epidural; Infiltration; Perineural, Injection - Epidural; Perineural, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Kit, Epidural; Infiltration; Intramuscular; Intravenous; Perineural; Topical, Injection - Epidural; Infiltration

Warnings

Naropin has one prohibition, so it should not be used when dealing with any of the conditions in the following table.

Naropin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Ropivacaine may interact with Pulse Frequency

There are 20 known major drug interactions with Naropin.

Common Naropin Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Ethanol

Major

Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Oliceridine

Major

The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Ropivacaine is combined with Oliceridine.

Technetium Tc-99m tilmanocept

Major

Ropivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.

Thalidomide

Major

Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Naropin Toxicity & Overdose Risk

Taking too much ropivacaine can harm the central nervous system and cardiovascular system. Symptoms include nervousness, tingling, ringing in the ears, shaking, dizziness, blurry vision, drowsiness, loss of consciousness, shallow breathing, low blood pressure, slow heartbeat, irregular heartbeat, and cardiac arrest.

Naropin Novel Uses: Which Conditions Have a Clinical Trial Featuring Naropin?

30 trials are actively assessing the impact of Naropin on providing Surgical Anesthesia, Acute Pain and Anesthesia procedures.

Condition

Clinical Trials

Trial Phases

Labour

2 Actively Recruiting

Phase 4, Phase 3

Acute Pain

1 Actively Recruiting

Not Applicable

Anesthesia procedures

0 Actively Recruiting

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Naropin Reviews: What are patients saying about Naropin?

5

Patient Review

3/7/2009

Naropin for Regional Anesthesia for Post-Operative Pain

I had rotator cuff surgery and was amazed at how painless it was until the pump ran out.

5

Patient Review

10/8/2009

Naropin for Regional Anesthesia for Post-Operative Pain

Had surgery on my rotator cuff and it was a total success! I barely felt any pain afterwards and the treatment only lasted for 42-43 hours. I would highly recommend this to anyone considering it.

5

Patient Review

10/15/2010

Naropin for Regional Anesthesia for Post-Operative Pain

This was a very effective treatment for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about naropin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Naropin used for?

"Naropin is a type of local anaesthesia which is used in a spinal block, or epidural. It is used to provide anaesthesia during a surgery or C-section, or to ease labour pains."

Answered by AI

How long does it take for ropivacaine to start working?

"Ropivacaine can be used to produce surgical anaesthesia or a sensory block. These effects usually begin within a few minutes and last for 2-6 hours when ropivacaine is used for field blocks."

Answered by AI

How long does ropivacaine block last?

"For ropivacaine, the shortest time it will work is 3.75 hours, the longest time it will work is 9 hours, most of the time it will work for between 5.1 and 7.04 hours, and on average it will work for 6 hours."

Answered by AI

What type of drug is Naropin?

"Ropivacaine is used for local or regional anesthesia during surgery. It is marketed by AstraZeneca under the trade name Naropin."

Answered by AI

Clinical Trials for Naropin

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Have you considered Naropin clinical trials?

We made a collection of clinical trials featuring Naropin, we think they might fit your search criteria.
Go to Trials
Image of UI Health Care Center for Advanced Reproductive Care in Iowa City, United States.

Ketorolac for Infertility Treatment

18 - 37
Female
Iowa City, IA

Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy. However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle). Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research. This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would. Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia. Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.

Phase 4
Recruiting

UI Health Care Center for Advanced Reproductive Care

Image of Thomas Jefferson University in Philadelphia, United States.

Physical Therapy for Ventral Hernia

18 - 75
All Sexes
Philadelphia, PA

The goal of this clinical trial is to evaluate the efficacy, safety, and cost-effectiveness of a tailored physical therapy (PT) intervention targeting Abdominal Core Health components in patients recovering from ventral hernia repair. The study focuses on patients aged 18-75 diagnosed with a ventral transverse hernia between 4 cm and 10 cm, scheduled for elective Ventral Hernia Repair (VHR). The main questions it aims to answer are: * Will tailored PT significantly improve abdominal core strength, biomechanical stability, and functional mobility compared to usual care at 3-months post-surgery? * Will tailored PT lead to higher patient-reported quality of life and satisfaction scores, with a lower incidence of post-operative complications such as bowel obstruction and pelvic floor dysfunction over a 1-year follow-up? * Will tailored PT result in decreased healthcare utilization, leading to overall cost savings or neutrality compared to usual care over the first year after VHR? Researchers will compare the tailored physical therapy group to a usual care group to see if the tailored intervention leads to significant improvements in clinical efficacy, patient outcomes, and cost-effectiveness. Participants will: * Be randomly assigned to either the Usual Care Group or the PT Group. * If in the Usual Care Group, receive standard post-operative instructions for 12 weeks, including guidance on binder use, safe lifting, and gradual return to activities. * If in the PT Group, receive foundational post-operative instructions for the first 2 weeks (similar to usual care). Undergo 6 structured and individualized PT sessions over 10 weeks if in the PT Group, with progression based on Oswestry Disability Index (ODI) and Pelvic Floor Distress Inventory-20 (PFDI-20) scores, including Symptom Modulation, Movement Control, Functional Optimization, or Impairment-Based interventions. Participants undergo data collection at 2 weeks, 12 weeks, and 1 year post-operation, including imaging, functional mobility tests, pain scales, patient-reported outcomes, physical measurements, and tracking of complications and healthcare utilization. Participate in semi-structured interviews after the 12-week assessment to provide qualitative insights into their experiences and perceived barriers/facilitators.

Waitlist Available
Has No Placebo

Thomas Jefferson University

Christopher Keating

Have you considered Naropin clinical trials?

We made a collection of clinical trials featuring Naropin, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Glen Site) in Montreal, Canada.

Opioid-Free vs Opioid Analgesia for Postoperative Pain

18+
All Sexes
Montreal, Canada

North America is experiencing a crisis of opioid use and abuse, partially caused by excessive prescribing by doctors. People often receive their first opioid prescription for pain treatment after outpatient breast surgery (i.e., surgery to remove all or parts of the breast(s), where patients leave the hospital the same day). Many patients misuse these drugs and become addicted. Additionally, many of the opioid pills prescribed to patients are left unused and may be misused by family members, friends, or other community members. To prevent this problem, surgeons can avoid prescribing opioids by prioritizing opioid-free analgesia (i.e., pain treatment using only non-opioid interventions). Prescribing only non-opioid pain medications after surgery is very common in many countries outside of North America; however, few studies have assessed whether opioid-free analgesia is as effective as opioid analgesia after breast surgery. Therefore, the main question driving this study is: For patients who undergo outpatient breast surgery, is pain treatment without opioids as good as pain treatment with opioids? The proposed trial will compare two groups of patients: one group will receive opioids to treat pain after surgery, while the other group will receive only non-opioid medications. The impact of these different medication strategies will be measured on pain intensity, pain interference with daily activities, medication side effects, and other outcomes. An expert team of scientists, surgeons, pain specialists, nurses, and patients has been assembled to maximize the success of this study. The results will provide important information to guide surgeons' decisions to prescribe (or not to prescribe) opioids. If opioid-free analgesia is found to be effective, doctors may be able to substantially reduce opioid prescribing after breast surgery and prevent more people from misusing opioids.

Recruiting
Has No Placebo

McGill University Health Centre (Glen Site)

Julio Flavio Fiore, PhD

Have you considered Naropin clinical trials?

We made a collection of clinical trials featuring Naropin, we think they might fit your search criteria.
Go to Trials